Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD). It also provides immunoglobulin products that comprise KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company offers other products, including Heparin Lock Flush to maintain patency of indwelling IV catheter; Kamacaine 0.5% used as anesthesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; and Human Transferrin, which is used as a cultural medium for diagnostic assays and cell cultures. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. Additionally, it provides Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of blood plasma. Kamada Ltd. also offers coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Baxter International Inc.; Chiesi Farmaceutici; PARI GmbH; and Kedrion S.p.A. The company was founded in 1990 and is headquartered in Rehovot, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-8940-6472
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$102.82 million
Profitability
Miscellaneous
Employees413
OptionableNot Optionable
Kamada (NASDAQ:KMDA) Frequently Asked Questions
What is Kamada's stock symbol?
Kamada trades on the NASDAQ under the ticker symbol "KMDA."
How were Kamada's earnings last quarter?
Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings results on Monday, November, 12th. The biotechnology company reported ($0.06) EPS for the quarter, missing the Zacks' consensus estimate of ($0.01) by $0.05. The biotechnology company earned $14.98 million during the quarter, compared to analysts' expectations of $25.99 million. Kamada had a return on equity of 11.70% and a net margin of 10.60%. View Kamada's Earnings History.
When is Kamada's next earnings date?
What guidance has Kamada issued on next quarter's earnings?
Kamada updated its FY 2018 earnings guidance on Monday, November, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $102-108 million, compared to the consensus revenue estimate of $111.59 million.Kamada also updated its FY 2019 guidance to EPS.
What price target have analysts set for KMDA?
2 Wall Street analysts have issued twelve-month target prices for Kamada's shares. Their predictions range from $7.00 to $11.00. On average, they anticipate Kamada's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 68.9% from the stock's current price. View Analyst Price Targets for Kamada.
What is the consensus analysts' recommendation for Kamada?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kamada.
Has Kamada been receiving favorable news coverage?
Headlines about KMDA stock have been trending somewhat negative on Sunday, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kamada earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Kamada's key competitors?
Some companies that are related to Kamada include Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Athenex (ATNX), Radius Health (RDUS), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), ImmunoGen (IMGN), Epizyme (EPZM), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), G1 Therapeutics (GTHX), AC Immune (ACIU), Urogen Pharma (URGN) and Rocket Pharmaceuticals (RCKT).
Who are Kamada's key executives?
Kamada's management team includes the folowing people:
- Mr. Amir London, Chief Exec. Officer (Age 50)
- Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 68)
- Mr. Eran Nir, VP of Operations & Plant Mang. (Age 46)
- Dr. Naveh Tov M.D., Ph.D., VP of Clinical Devel. & Medical Director for Pulmonary Diseases (Age 55)
- Mr. Chaime Orlev, Chief Financial Officer (Age 49)
How do I buy shares of Kamada?
Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kamada's stock price today?
One share of KMDA stock can currently be purchased for approximately $5.33.
How big of a company is Kamada?
Kamada has a market capitalization of $214.60 million and generates $102.82 million in revenue each year. The biotechnology company earns $6.90 million in net income (profit) each year or $0.18 on an earnings per share basis. Kamada employs 413 workers across the globe.
What is Kamada's official website?
How can I contact Kamada?
Kamada's mailing address is 2 HOLTZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]
MarketBeat Community Rating for Kamada (NASDAQ KMDA)
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
